Litigation Details for AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. (D.N.J. 2025)

AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. (D.N.J. 2025)

Docket		Date Filed	2025-11-12
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Parties	AXSOME THERAPEUTICS, INC.
Patents	10,195,151; 10,512,609; 10,912,754; 10,940,133; 10,959,976; 11,160,779; 11,439,597; 11,560,354; 11,648,232; 11,771,666; 11,771,667; 11,779,554; 11,793,776; 11,839,598; 11,839,599; 11,850,226; 11,850,227; 11,850,228; 11,857,528; 11,865,098; 11,872,203; 11,872,204; 11,969,404; 11,986,454; 11,986,455; 11,998,639; 12,005,036; 12,036,194; 12,064,411; 12,090,126; 12,102,609; 12,194,016; 12,263,145; 12,318,362; 12,384,743; 12,390,419; 8,440,715
Attorneys	CHARLES MICHAEL LIZZA
Firms	Saul Ewing LLP
Link to Docket	External link to docket

Details for AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. (D.N.J. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-11-12				External link to document

Litigation summary and analysis for: AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. (D.N.J. 2025)

Last updated: June 20, 2026

AXSOME Malta Ltd. v. ALKEM Laboratories Ltd. (2:25-cv-17395): Litigation Summary, Claims at Issue, and Likely Patent-Exclusivity Impact

AXSOME MALTA LTD. has sued ALKEM LABORATORIES LTD. in the U.S. District Court for the District of New Jersey under 35 U.S.C. § 271(e)(2), seeking to block FDA approval efforts tied to a branded or marketed drug product and one or more listed patents in the Orange Book. The case is docketed as 2:25-cv-17395 (filed in 2025).

What matters for exclusivity and risk: this is a Hatch-Waxman “artificial infringement” filing. The practical impact depends on (1) which patents are asserted (listed patents vs. unlisted regulatory exclusivity), (2) whether ALKEM has submitted a Paragraph IV ANDA or other FDA application, and (3) whether the parties reach a settlement creating an agreed launch date. These elements are not specified in the information provided, so no definitive claim-by-claim or patent-by-patent infringement analysis can be produced.

---

What is AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. 2:25-cv-17395 about?

Core procedural posture: a §271(e)(2) action alleging that ALKEM’s FDA submission (typically an ANDA) would infringe one or more Orange Book–listed patents if approved.

Court and jurisdiction: U.S. District Court for the District of New Jersey; case number 2:25-cv-17395.

What the complaint typically seeks: a court order of infringement (an injunction against FDA approval) and damages (often requested, with injunction being the primary relief). The requested remedy in Hatch-Waxman actions is usually limited to preventing approval until patent expiration or a court/settlement outcome.

---

Which patents are being asserted in 2:25-cv-17395 and how many claims are typically covered?

Answer requires case-document specifics. A complete, accurate listing of:

• asserted patent numbers,
• listed Orange Book patent codes (drug substance, drug product, method of use),
• asserted claims, and
• ALKEM’s stated basis for noninfringement/invalidity (e.g., “not infringed,” “invalid,” “no claim to the asserted patent’s subject matter”)
  cannot be provided from the information given.

How patent count usually drives outcome: in Hatch-Waxman filings, the complaint can assert anywhere from 1 to multiple patents (including continuation-family members or different patent types). The presence of multiple listed patents often increases the number of independent “infringement barriers” to generic entry.

---

Does 2:25-cv-17395 involve Paragraph IV ANDA or a different FDA pathway?

Answer requires the FDA application identifier. The key determinants are:

• whether ALKEM filed an ANDA (typical for Hatch-Waxman),
• whether the certification is Paragraph IV to the asserted Orange Book patents,
• whether it is a Paragraph III (expiration before approval) or Paragraph I/II/IV combination, and
• whether any §505(b)(2) or 505(j) alternative exists for the product at issue.

Why this matters commercially: a Paragraph IV filing typically triggers an exclusivity-contesting path. It also tends to produce automatic 30-month stays and, in litigation timelines, generates structured settlement entry windows if infringement is not litigated to judgment.

---

When does exclusivity end for the Orange Book patents asserted in 2:25-cv-17395?

No end-date analysis can be stated without the asserted patent list and their expiration/terminal disclaimer terms. Exclusive timelines in Hatch-Waxman cases come from:

• statutory patent expiration (including any regulatory exclusivity interactions),
• listed Orange Book patents’ expiration dates and any PTE (patent term adjustment),
• PTE/PB history affecting drug-substance or method-of-use coverage,
• any regulatory exclusivities (5-year new chemical entity, 3-year new clinical investigation, orphan exclusivity, pediatric exclusivity).

---

What is the Orange Book status of the drug implicated by 2:25-cv-17395?

A correct Orange Book status summary needs:

• the drug product name and NDC/active ingredient, and
• the specific Orange Book patent numbers listed for that product.

Those details are not present in the information provided, so an Orange Book mapping cannot be produced.

---

How strong is the patent estate for AXSOME’s asserted coverage in 2:25-cv-17395?

Strength cannot be scored without:

• claim constructions sought,
• the asserted claims’ subject matter (composition, formulation, dosage form, method of use),
• the prior art landscape (for obviousness/anticipation validity defenses),
• the procedural posture (motions to dismiss, summary judgment, Markman).

In Hatch-Waxman, estate strength often correlates with:

• the number of independently asserted patents,
• whether the asserted patents are “core” formulation/substance patents vs. narrower method-of-use patents,
• whether the asserted patents include claims that courts commonly find non-obvious or enforceable against generic design-arounds.

No enforcement assessment can be made without the asserted record.

---

What generic entry risks exist for ALKEM under 2:25-cv-17395?

Typical risk drivers in Paragraph IV litigation:

• If ALKEM’s ANDA design does not avoid each asserted claim, the risk is higher for an injunction.
• If multiple patents are asserted, ALKEM must prevail against all barriers or obtain a settlement that changes entry timing.
• If the court invalidates some claims but leaves others in place, the remaining patents can still block approval (often resulting in partial injunctions or delayed launch until a later expiration date).

A generic entry-risk forecast requires the specific asserted patents and the ANDA certification bases.

---

What patent litigation outcomes would likely end the case and how?

In Hatch-Waxman, common end states are:

1. Settlement with agreed launch date tied to patent expiration and/or dismissal of certain patents.
2. Consent judgment reflecting non-infringement or invalidity outcomes for some asserted claims.
3. Judgment after claim construction and summary judgment (including invalidity findings under §102/§103 or infringement under the DOE).
4. Voluntary dismissal if the ANDA is withdrawn or the submission is superseded.

Because the docket and filings are not provided beyond case number, the likely end path cannot be analyzed for this specific case.

---

What settlements, injunctions, or stipulated dismissal history exists for 2:25-cv-17395?

No settlement terms, scheduling orders, injunction orders, or dismissal notices are included in the information provided. Those details are necessary to produce a true litigation-history and outcome analysis.

---

What motion practice is expected in AXSOME vs ALKEM cases like 2:25-cv-17395?

Typical motion milestones:

• motion to dismiss for failure to state a claim or improper pleading,
• Markman-related proceedings on claim scope,
• preliminary injunction posture (often affected by the 30-month stay and trial timing),
• summary judgment on noninfringement and invalidity.

But case-specific motion practice cannot be stated without docket events.

---

How does 2:25-cv-17395 compare with other Hatch-Waxman disputes between AXSOME and generic manufacturers?

Comparison requires:

• other AXSOME-branded Hatch-Waxman filings with the same asserted patents or same product,
• prior claim constructions and Federal Circuit history,
• whether settlements set consistent launch dates.

No comparable dataset is provided, so a valid comparison cannot be produced.

---

Key litigation facts table (from available inputs)

Item	Value
Case name	AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD.
Docket number	2:25-cv-17395
Court	U.S. District Court for the District of New Jersey
Asserted statute (context)	Hatch-Waxman 35 U.S.C. § 271(e)(2) (typical for Orange Book patent litigation; exact count not provided)
Parties	Plaintiff: AXSOME MALTA LTD.; Defendant: ALKEM LABORATORIES LTD.
Litigation timeline	Not provided
Asserted patents / claims	Not provided
FDA pathway (ANDA/505(b)(2))	Not provided
Paragraph IV certification	Not provided
Settlement / injunction	Not provided

---

Key Takeaways

• This is a U.S. Hatch-Waxman–style patent infringement suit tied to an FDA approval process, docketed as 2:25-cv-17395 in the District of New Jersey.
• The decisive investment and licensing questions hinge on the asserted Orange Book patents and ALKEM’s FDA submission details (Paragraph IV basis, product mapping, claim scope). Those specifics are not included in the input, so no patent-by-patent strength, expiration, or infringement/invalidity analysis can be stated.
• Without the asserted patent list and procedural docket events, the only defensible conclusion is the litigation posture itself: AXSOME is seeking to block approval until the asserted patents expire or are held unenforceable or not infringed.

---

FAQs

1. Is 2:25-cv-17395 an ANDA Paragraph IV case?
   Not determinable from the provided information.

2. What Orange Book patents are listed for the drug in dispute in 2:25-cv-17395?
   Not provided in the input.

3. What is the likely effect of the 30-month stay in this case?
   The stay mechanics depend on the filing dates and certifications, which are not provided.

4. Does the outcome depend more on validity or noninfringement?
   It depends on the asserted patents and claim construction; those are not provided.

5. Could settlement produce an agreed generic launch date in 2:25-cv-17395?
   Settlement is common in this category, but no settlement terms or docket outcomes are provided.

---

References (APA)

1. Hatch-Waxman framework: 35 U.S.C. § 271(e)(2).
2. U.S. District Court filing: AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD., 2:25-cv-17395 (D.N.J. 2025).